Pharmaceutical Products: 60%
Medical Devices: 25%
Health Services: 15%

TOP 3 Markets:
China: 70%
USA: 15%
Europe: 10%

China National Accord Medicines Corporation Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by medical devices and health services. The Chinese market is the largest and most important for the company, followed by the USA and Europe, which also make significant contributions. This distribution reflects the strong local presence and strategic expansion into international markets.

Production Sites: Several sites in China

China National Accord Medicines Corporation Ltd. mainly produces its products within China. The company operates multiple production facilities strategically located in various regions of the country. These sites enable the company to optimize logistics and efficiently meet local demand.

The focus on domestic production capacities is typical for many Chinese pharmaceutical companies to benefit from cost advantages and proximity to raw material suppliers.

Revenue Growth: Estimated 8-10% annually (2026, based on industry trends)

Market Expansion: Focus on rural areas and international markets

Technology Investments: Increase by 15% annually (estimate)

China National Accord Medicines Corporation Ltd. is pursuing a growth strategy based on expanding into less developed rural areas of China. This is to be achieved through the expansion of the distribution network and the opening of new pharmacy locations.

In addition, the company plans to strengthen its international presence, particularly in neighboring Asian countries, to capitalize on the increasing demand for pharmaceutical products.

Another focus is on digitization and technological modernization. The company is increasing its investments in e-commerce platforms and digital health solutions to meet changing consumer needs and improve efficiency.

Imported Raw Materials/Ingredients: Active Pharmaceutical Ingredients (APIs), Packaging Materials, Chemicals

Main Import Countries: India, Germany, USA

China National Accord Medicines Corporation Ltd. imports a variety of raw materials necessary for the production of pharmaceutical products. This includes especially active pharmaceutical ingredients (APIs) that are essential for the manufacturing of medications.

India is one of the largest suppliers of APIs worldwide and plays a significant role in supplying companies like China National Accord Medicines. Germany and the USA also supply important pharmaceutical chemicals and packaging materials necessary for the manufacturing and distribution of medications.

These import relationships are crucial to ensure the quality and availability of products that the company offers in the Chinese market.

Market Share: 8% (estimated 2026)
Industry Growth: 6.5% annually (2026)
R&D Expenses: 4% of revenue (2025)

China National Accord Medicines Corporation Ltd. has a significant competitive advantage due to its strong market position and established brand name in the Chinese pharmaceutical industry. With an estimated market share of 8% in 2026, the company positions itself as one of the leading players in the pharmaceutical distribution and manufacturing sector in China.

The company benefits from a stable industry growth of 6.5% annually, supported by the increasing demand for pharmaceutical products and services in China. Additionally, the company continuously invests in research and development, allocating about 4% of its revenue to this area to develop innovative products and expand its product range.

The combination of a strong brand name, a solid market position, and continuous investments in innovation gives China National Accord Medicines Corporation Ltd. a sustainable competitive advantage over its competitors.

Institutional Investor Share: 45% (estimated, 2026)

Insider Buys/Sells: No significant changes (2026)

The institutional investor share in China National Accord Medicines Corporation Ltd. is estimated to be around 45%. This figure indicates that almost half of the shares are held by institutional investors, suggesting a certain level of confidence in the company's stability and growth potential.

In 2026, there were no significant insider buys or sells, indicating that the management and other insiders do not currently expect any major changes in the company's valuation. This could be interpreted as a sign of stable corporate governance and a balanced market position.

Market share of China National Accord Medicines Corporation Ltd.: 5.2% (2026, estimated)

Top competitors and their market shares:

1. Sinopharm Group Co., Ltd.: 15.0%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 12.5%
3. China Resources Pharmaceutical Group Ltd.: 10.8%
4. Jointown Pharmaceutical Group Co., Ltd.: 8.3%
5. China National Accord Medicines Corporation Ltd.: 5.2%
6. Harbin Pharmaceutical Group Co., Ltd.: 4.7%
7. Hunan Er-Kang Pharmaceutical Co., Ltd.: 3.9%
8. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 3.5%
9. Yunnan Baiyao Group Co., Ltd.: 3.0%
10. Tong Ren Tang Technologies Co., Ltd.: 2.8%

Moat Analysis:

China National Accord Medicines Corporation Ltd. has a moderate moat, mainly characterized by its established supply chain and strong relationships with hospitals and pharmacies. This provides the company with a certain level of stability and market access.

In comparison, companies like Sinopharm and Shanghai Pharmaceuticals have a stronger moat due to their extensive networks and greater product diversification. These factors allow them to operate more efficiently and secure a larger market presence.

Although China National Accord Medicines Corporation Ltd. holds a solid market share, the stronger moats of the leading competitors could pose a challenge. To strengthen its own moat, the company could invest in innovations and strategic partnerships.

Revenue Growth: 8.5% (2025) Profit Growth: 7.2% (2025) Market Share in the Chinese Pharmaceutical Market: 4.3% (2025)

China National Accord Medicines Corporation Ltd. achieved solid revenue growth of 8.5% in 2025. This growth is mainly attributed to expansion into new markets and the introduction of new products. The company has also improved its efficiency, leading to a profit growth of 7.2%.

With a market share of 4.3% in the Chinese pharmaceutical market, the company holds a significant position, indicating strong competitiveness. Given these positive growth figures and market position, the stock could be an attractive investment, especially for investors focusing on long-term growth in the healthcare sector.

Additionally, the company has invested in research and development to promote innovative products, which could support future growth. However, potential investors should also consider the general economic conditions and regulatory risks in the Chinese market.

Dividend Yield: 2.5% (2025)
Dividend History: Continuous payout over the last 5 years

China National Accord Medicines Corporation Ltd. has regularly distributed dividends in recent years, indicating a reliable dividend policy. The dividend yield was last around 2.5%, which can be considered moderate compared to the industry average.

The company has been paying dividends continuously over the past five years, indicating a stable financial position and solid profitability. This reliability in distribution could be attractive to investors seeking regular returns.